Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Sep 1;56(5):317-321.
doi: 10.4103/ijp.ijp_107_24. Epub 2024 Dec 16.

Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients

Razia Abdul Rasheed  1 , G Venkatraman  2 , S Vijayalakshmi  1 , T A R Raja  1 , G Senthil  1 , P Renugadevi  1
Affiliations
Randomized Controlled Trial

Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients

Razia Abdul Rasheed et al. Indian J Pharmacol. .

Abstract

Background: Long-term metabolic disease type 2 diabetes mellitus (T2DM) is distinguished by elevated blood glucose, insulin resistance, and drought of insulin with dyslipidemia. Oral hypoglycemic agents lower blood glucose levels as well as prevent both short-term and long-term complications such as micro/macrovascular atherosclerosis, chronic kidney diseases, and chronic heart disease. This study aims to compare the effect of glimepiride versus teneligliptin in combination with metformin in T2DM patients attending a tertiary care hospital.

Materials and methods: This prospective, randomized, open-label study was initiated in a tertiary care hospital after obtaining IEC approval. Written informed consent was obtained. The sample size was calculated using "Statistics and sample size software." Ninety-seven patients satisfying the inclusion criteria were assigned to two groups using simple randomization with allocation 1:1. Group A received metformin + glimepiride while Group B received metformin + teneligliptin for 12 weeks. Fasting blood sugar (FBS), postprandial blood sugar (PPBS), glycated hemoglobin (HbA1c), and lipid profile were recorded at the baseline and at the end of 12 weeks. This study was conducted for 1 year. Data were analyzed using SPSS version 23.0 software.

Results: Out of 97 participants (Group A: 48 and Group B: 49), Group A showed a higher reduction in FBS (48.18 ± 9.64) whereas Group B showed 72.53 ± 5.01, 1.74 ± 0.42 of change in PPBS and HbA1c after 12 weeks.

Conclusion: The study found that combining metformin with teneligliptin was better tolerated and improved glycemic control and lipid profile compared to metformin plus glimepiride.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Patient disposition chart
See this image and copyright information in PMC

References

    1. Bailes BK. Diabetes mellitus and its chronic complications. AORN J. 2002;76:266–76. 278-82. - PubMed
    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html .
    1. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019. Results. Institute for Health Metrics and Evaluation. 2020. [[Last accessed on 2023 May]]. Available from: https://vizhub.healthdata.org/gbd-results/
    1. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.
    1. Cloete L. Diabetes mellitus: An overview of the types, symptoms, complications and management. Nurs Stand. 2022;37:61–6. - PubMed

Publication types

MeSH terms